BALTIMORE – Regulators and industry representatives said that a new international guideline for evaluating the benefit-risk profile of new and marketed drugs developed by the Council for International ...
CDRH has issued a first-of-a-kind guidance: "Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications [PDF link]." The guidance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results